Haloperidol: Nursing Drug Guide, Extrapyramidal Symptoms & NCLEX Review

Haloperidol is a first-generation (typical) butyrophenone antipsychotic available generically and historically marketed under the brand Haldol in the United States. Verify formulation on the MAR—oral tablets, oral concentrate, IM lactate injection, and long-acting decanoate injection are not interchangeable milligram-for-milligram.

Oral tablet strengths per labeling include 0.5, 1, 2, 5, 10, and 20 mg. IM haloperidol lactate injection commonly provides 5 mg/mL for intramuscular use. Haloperidol decanoate is a separate long-acting depot product—never substitute depot for immediate-release IM or oral doses without prescriber and pharmacy verification.

Haloperidol is a high-potency typical antipsychotic with strong dopamine D₂ blockade—nurses most often see it for acute agitation, psychotic disorders, and behavioral emergencies where rapid EPS and QT risk must be weighed against calming benefit.

↔On a small screen, swipe or scroll sideways to see the full table.

The precise mechanism of action has not been clearly established per labeling. Haloperidol is a potent typical antipsychotic with strong central dopamine antagonism—this underlies antipsychotic effect and also drives extrapyramidal symptoms, hyperprolactinemia, and the motor side effects nurses must screen for after every dose. Compared with low-potency phenothiazines, haloperidol generally causes more EPS and less anticholinergic sedation at equivalent antipsychotic effect—do not assume a low milligram dose is low risk.

Dosage should be individualized according to patient needs and response; children, debilitated, and geriatric patients usually require lower doses and slower titration per labeling. Higher-than-recommended doses increase QT-prolongation and EPS risk.

Missed dose: Not specified in the reviewed prescribing information. Do not double doses; abrupt withdrawal after maintenance therapy may cause transient dyskinetic signs—gradual taper per labeling when discontinuing.

↔On a small screen, swipe or scroll sideways to see the full table.

Titration

Adjust upward or downward as rapidly as practicable to achieve optimum control while using the smallest effective maintenance dose. Reassess need for continued therapy periodically because tardive dyskinesia risk increases with duration and cumulative dose per labeling.

Pretreatment checks

• Confirm indication is not dementia-related psychosis (boxed warning—drug not approved); review haloperidol hypersensitivity and Parkinson disease (contraindicated)
• Review baseline basic metabolic panel for potassium and magnesium; obtain ECG when QT risk factors or IV injection use is present per labeling
• Screen QT-prolonging co-medications, CNS depressants, anticonvulsants, and epilepsy history (haloperidol may lower seizure threshold); obtain CBC baseline if low WBC or prior drug-induced neutropenia

Contraindications

• Severe toxic CNS depression or comatose states from any cause
• Hypersensitivity to haloperidol
• Parkinson disease

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Route: Oral tablets and concentrate; haloperidol lactate IM injection (5 mg/mL) per labeling. Haloperidol injection is not approved for intravenous administration—if IV is given off-label, ECG monitoring for QT prolongation and arrhythmias is advised per labeling.

• Oral: use calibrated device for concentrates; verify tablet strength (0.5–20 mg)—small milligram differences matter with high potency
• IM: follow IM injection technique; typical acute dose 2–5 mg; observe for acute dystonia and hypotension after injection
• Switch from parenteral to oral within 12–24 hours of last parenteral dose using careful clinical monitoring during switchover per labeling

• Reduced agitation, hallucinations, or disorganized thought without new severe EPS or excessive sedation that blocks assessment
• Improved cooperation and decreased psychomotor agitation in acute schizophrenia or behavioral emergencies when dose is appropriate
• Stable vitals, normal swallowing, and absence of rising temperature or rigidity after dosing—therapeutic calm should not mask NMS early signs

Treat sudden neurologic, cardiac, or autonomic changes as urgent until proven otherwise. Haloperidol overdose has no specific antidote—supportive care and ECG monitoring are essential.

• Acute dystonia: neck spasm, tongue protrusion, oculogyric crisis, swallowing or breathing difficulty—especially within days of dose increase in younger males
• Hyperpyrexia, muscle rigidity, altered mental status, diaphoresis, tachycardia, or irregular BP suggesting neuroleptic malignant syndrome (NMS)
• Palpitations, syncope, or new ventricular arrhythmia in a patient with QT risk factors or recent high-dose/IV haloperidol
• Confusion with fever and leukocytosis on lithium co-therapy—possible encephalopathic syndrome; stop and escalate
• Fever with sore throat and falling WBC—possible agranulocytosis; discontinue and obtain CBC per labeling
• New jaundice or impaired liver function reported with haloperidol—stop drug and notify prescriber

↔On a small screen, swipe or scroll sideways to see the full table.

Overdose manifestations are an exaggeration of pharmacologic effects: severe EPS, hypotension (or hypertension in one pediatric case report), and sedation/coma with respiratory depression per labeling. ECG changes and Torsades de pointes risk should be considered.

Antidote

No specific antidote is listed in the reviewed prescribing information. Treatment is primarily supportive.

• Gastric lavage or emesis induction followed by activated charcoal when appropriate and airway is protected
• Establish patent airway; artificial respiration/mechanical ventilation for respiratory depression
• Severe EPS: administer antiparkinson medication (benztropine or trihexyphenidyl per labeling; diphenhydramine may be used per institutional protocol aligned with labeling examples)
• Hypotension: IV fluids, plasma/albumin, vasopressors—metaraminol, phenylephrine, or norepinephrine; epinephrine is contraindicated per labeling
• Monitor ECG and vitals until QT normalizes; treat severe arrhythmias with appropriate antiarrhythmic measures per labeling

• Haloperidol vs Haldol — verify generic and brand on MAR and pump labels
• Haloperidol lactate IM vs haloperidol decanoate depot — immediate-release versus long-acting; never substitute without prescriber/pharmacy confirmation
• Haloperidol vs chlorpromazine — both antipsychotics but different potency/EPS profiles; LASA verification on behavioral-health orders
• Oral tablet strength mix-ups — 0.5 mg vs 5 mg vs 20 mg; independent double-check high-potency low-milligram orders
• mg vs mL in injection (5 mg/mL) — calculate total mg carefully; max 20 mg/day IM per injection labeling unless prescriber documents exception
• IV push without approval — injection product is not approved IV; off-label IV use requires ECG monitoring per labeling

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Extrapyramidal signs (restlessness, rigidity, tremor, swallowing) and temperature/autonomic status for NMS—use structured neurological assessment
• ECG and electrolytes (K⁺, Mg²⁺) when QT risk factors, high doses, or IV injection use; compare to baseline tracing
• CBC frequently during first months if low baseline WBC or prior drug-induced neutropenia—discontinue at first WBC decline without other cause per labeling
• Level of consciousness, gait, orthostatic vitals when sedated, and intake/output in patients at dehydration risk per labeling warnings

Document

• Dose, route, time, indication, EPS assessment, and behavioral response (not just sedation)
• ECG/electrolyte results, PRN antiparkinson doses given, and prescriber/pharmacist notifications for dystonia, QT changes, or fever
• Patient teaching on reporting rigid muscles, fever, abnormal movements, palpitations, and swallowing difficulty

• Report neck stiffness, tongue swelling, eye-rolling, trouble swallowing, or breathing difficulty immediately—these may be acute dystonia
• Report fever with stiff muscles, confusion, or fast/irregular heartbeat—possible NMS or cardiac toxicity
• Do not drive or operate machinery until you know how haloperidol affects alertness; avoid alcohol and extra sedatives unless prescribed
• Tell your care team about palpitations, fainting, or new involuntary mouth or limb movements (possible tardive dyskinesia)
• Do not stop haloperidol suddenly without prescriber guidance—withdrawal emergent dyskinesia may occur after abrupt discontinuation per labeling

Do not give and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Rehearse NCLEX-style clinical judgment practice for haloperidol using a tabbed case (MAR, labs, vitals, nursing notes), then priority action, EPS cue recognition, electrolyte/QT trend interpretation, matrix urgency sorting, dystonia judgment, and vasopressor cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.